Is argenx SE halal to invest in?

As of August 2026, argenx SE ARGX.VI is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is argenx SE a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes argenx SE using these criteria to determine its compliance status.

Can Muslims buy shares of argenx SE?

Muslim investors may consider investing in argenx SE if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is argenx SE classified as HALAL?

Musaffa determines the Shariah status of argenx SE by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for argenx SE updated?

The Shariah compliance status of argenx SE may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like argenx SE become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of argenx SE?

You can check the latest Shariah compliance status of argenx SE on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

argenx SE ARGX.VI

Last Updated: Aug 07, 12:00 AM·WBAG

ARGX.VI Shariah Compliance

Screening Methodology: AAOIFI

As of August 2026, argenx SE is classified as halal.

HALAL

Report Source: undefined Quarter Report

argenx SE. Stock Analysis ARGX.VI

Austria Health Care Large Cap

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.